Intriguingly, knocking down BCL9L suppressed the upregulation of CD133 in glioma cells cultured on 16-kPa gels, whereas overexpressing BCL9L further enhanced CD133 expression (Figure 2C and Supplementary Figure 1D). This evidence concerns the gene BCL9L and central nervous system cancer.